Core Viewpoint - Gongdong Medical (605369.SH) announced the early termination of the share reduction plan by major shareholders and the results of the share reduction [1] Group 1: Share Reduction Details - The company disclosed that Taizhou Jincheng Investment Management Partnership (Limited Partnership) planned to reduce its holdings by up to 1,575,784 shares, representing 1% of the total share capital [1] - The company's general manager, Zhong Weifeng, intended to reduce his holdings by up to 302,158 shares, accounting for 0.19% of the total share capital [1] - As of May 30, 2025, Jincheng Investment had reduced its holdings by 1,575,708 shares, while Zhong Weifeng had reduced 294,936 shares [1] Group 2: Financial Impact of Share Reduction - Zhong Weifeng's share reduction occurred between March 13, 2025, and May 30, 2025, with a total amount of 8,526,906.60 yuan at a price range of 28.08 to 30.98 yuan per share [2] - Jincheng Investment reduced its holdings from March 11, 2025, to May 30, 2025, totaling 43,171,696.32 yuan at a price range of 23.64 to 30.53 yuan per share [2] - The combined total amount from both parties' share reductions was 51,698,602.92 yuan [2] Group 3: Shareholding Structure - Prior to the reductions, Zhong Weifeng held 1,208,634 shares (0.77% of total share capital), while Jincheng Investment held 11,760,000 shares (7.46% of total share capital) [2] - After the reductions, Zhong Weifeng's holdings decreased to 913,698 shares (0.58%), and Jincheng Investment's holdings decreased to 10,184,292 shares (6.46%) [2] - The major shareholders, including Shi Huiyong and Shi Yibei, collectively held 102,688,600 shares, representing 65.17% of the total share capital [2][3]

Key Points - The core point of the article is the trading and shareholder activity of Gongdong Medical, highlighting a decrease in stock price and changes in major shareholders' positions [1][3]. Trading Information Summary - On May 30, 2025, Gongdong Medical's stock closed at 26.27 yuan, down 0.04%, with a turnover rate of 1.11% and a trading volume of 17,500 shares, resulting in a transaction amount of 46.5264 million yuan [1]. - The capital flow on the same day showed a net inflow of 6.0551 million yuan from main funds, while speculative funds experienced a net outflow of 6.2977 million yuan, and retail investors had a net inflow of 242,600 yuan [1][3]. Shareholder Changes Summary - On May 30, 2025, Gongdong Medical announced that shareholder Taizhou Jincheng Investment Management Partnership (Limited Partnership) reduced its holdings by a total of 1.3132 million shares, accounting for 0.8333% of the company's total share capital, during a period when the stock price fell by 9.41% [1]. - The announcement detailed that prior to the reduction, Jincheng Investment held 11,760,000 shares, representing 7.46% of the total share capital, while the company's director and general manager, Zhong Weifeng, held 1,208,634 shares, or 0.77% of the total [1]. - Jincheng Investment's planned reduction was for up to 1,575,784 shares, while Zhong Weifeng planned to reduce up to 302,158 shares. As of May 30, 2025, Jincheng Investment had reduced 1,575,708 shares and Zhong Weifeng had reduced 294,936 shares, with both deciding to terminate their reduction plans early [1][3].

Summary of Key Points Core Viewpoint - The announcement details the results of a share reduction plan by Zhejiang Gongdong Medical Instrument Co., Ltd, highlighting the amounts and percentages of shares sold by key stakeholders, including the early termination of the reduction plan [1][3]. Group 1: Shareholder Reduction Details - Taizhou Jinch Investment Management Partnership (Limited Partnership) planned to reduce its holdings by up to 1,575,784 shares, representing no more than 1% of the total share capital [1]. - The total shares reduced by Taizhou Jinch amounted to 1,575,708 shares, leaving it with 10,184,292 shares, which is 6.46% of the total share capital [1][3]. - Chairman and General Manager Zhong Weifeng planned to reduce his holdings by up to 302,158 shares, which is 0.19% of the total share capital, and he successfully reduced 294,936 shares, retaining 913,698 shares, or 0.58% of the total [1][3]. Group 2: Reduction Plan Implementation - The reduction period for Zhong Weifeng was from March 13, 2025, to May 30, 2025, with a total reduction amounting to 8,526,906.60 yuan at a price range of 28.08 to 30.98 yuan per share [2][3]. - Taizhou Jinch's reduction period was from March 11, 2025, to May 30, 2025, with a total reduction amounting to 43,171,696.32 yuan at a price range of 23.64 to 30.53 yuan per share [2][3]. - Both shareholders decided to terminate the reduction plan early, having met their planned reduction amounts [3].

证券代码：605369 证券简称：拱东医疗 公告编号：2025-022 重要内容提示： 减持主体持股的基本情况 本次减持计划实施前，台州金驰投资管理合伙企业（有限合伙）（以下简称 "金驰投资"）持有浙江拱东医疗器械股份有限公司（以下简称"公司"）股份 11,760,000 股，占公司总股本的 7.46%。公司董事、总经理钟卫峰持有公司股份 1,208,634 股，占公司总股本的 0.77%。 减持计划的实施结果情况 2025 年 2 月 17 日，公司披露了《5%以上股东、董事兼总经理集中竞价减持 股份计划公告》（公告编号：2025-003），金驰投资拟通过集中竞价交易方式合计 减持数量不超过 1,575,784 股，即不超过公司总股本的 1%；公司董事、总经理钟 卫峰拟通过集中竞价交易方式合计减持数量不超过 302,158 股，即不超过公司总 股本的 0.19%，不超过其持有公司股份总数的 25%。 2025 年 5 月 30 日，公司收到钟卫峰先生、金驰投资出具的《关于股份减持 结果的告知函》，金驰投资已通过集中竞价方式累计减持 1,575,708 股，钟卫峰先 生已通过集中竞价方式累计减持 294,93 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2025-021 浙江拱东医疗器械股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 27 日 (二)股东大会召开的地点：浙江拱东医疗器械股份有限公司（以下简称"公司" 或"拱东医疗"）三楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 66 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 113,816,345 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 72.3625 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长主持，董事会秘书记录，大会采 用现场投票和网络投票相结合的表决方式进行表决 ...

司 天册律师事务所 T & C LAW F I R M 法律意见书 浙江天册律师事务所 关于 浙江拱东医疗器械股份有限公司 2024 年年度股东大会的 法律意见书 天册律师事务所 T & C LAW FIRM 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话: 0571-8790111 传真: 0571-87901500 法律意见书 浙江天册律师事务所 关于浙江拱东医疗器械股份有限公司 2024 年年度股东大会的 法律意见书 编号:TCYJS2025H0636 号 致:浙江拱东医疗器械股份有限公司 浙江天册律师事务所(以下简称"本所")接受浙江拱东医疗器械股份有限公 司（以下简称"拱东医疗"或"公司"）的委托,指派本所律师参加公司 2024 年年 度股东大会,并根据《中华人民共和国证券法》(以下简称"《证券法》")、《中 华人民共和国公司法》(以下简称"《公司法》")和《上市公司股东会规则》(以 下简称《股东会规则》)等法律、法规和其他有关规范性文件的要求出具本法律意 见书。 在本法律意见书中,本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结 ...

资金流向方面，今日该股主力资金净流出46.19万元，其中，特大单净流入930.97万元，大单资金净流出 977.17万元。近5日主力资金净流出1.08亿元。 拱东医疗(605369)今日跌停，全天换手率3.81%，成交额1.61亿元，振幅3.03%。龙虎榜数据显示，机构 净买入996.71万元，沪股通净卖出3.11万元，营业部席位合计净买入1161.26万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.77%上榜，机构专用席位净买入996.71万元，沪股 通净卖出3.11万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5466.18万元，其中，买入成交额为 3810.52万元，卖出成交额为1655.66万元，合计净买入2154.85万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买二、买三、卖一，合计买入金额 1411.18万元，卖出金额414.47万元，合计净买入996.71万元，沪股通为第四大买入营业部及第五大卖出 营业部，买入金额为280.56万元，卖出金额为283.67万元，合计净卖出3.11万元。 4月26日公司发布的一季报数据显示，一季度公司共实现营业收入 ...

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's stock closed at 26.69 yuan, with a PE ratio of 27.32, marking a new low in 24 days [1] - The total market capitalization is 4.206 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 49.84, with a median of 36.59, placing Gongdong Medical at 61st in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, four institutions hold shares in Gongdong Medical, including two funds, with a total holding of 14.5259 million shares valued at 402 million yuan [1]

浙江拱东医疗器械股份有限公司 （浙江省台州市黄岩区北院大道10号） 2024年年度股东大会 会议资料 2025年5月 2、公司股东或者股东代理人参加会议，依法享有发言权、咨询权、表决权 等各项权利，会议进行中要求发言的股东或者股东代理人，应当先向会议主持人 提出申请，并经主持人同意后方可发言。 为维护股东的合法权益，确保会议秩序和议事效率，根据《公司法》《公司 章程》及《公司股东大会议事规则》等有关规定，特制定本次会议须知： | 案》 39 | | --- | 1、出席会议的股东或股东代理人需出示身份证明等材料的原件（材料清单 详见本次会议通知），经律师验证后办理签到手续并领取会议资料，除上述人员 和公司董监高、见证律师及董事会邀请的人员外，其他无关人员不得入场。在会 议主持人宣布会议开始时，会议登记终止。 浙江拱东医疗器械股份有限公司 2024 年年度股东大会会议须知 | | | 3、股东或股东代理人发言前认真做好准备，每一股东或股东代理人发言不 得超过 3 分钟。主持人可安排公司相关人员回答股东问题，与本次股东大会议题 无关或将泄露公司商业秘密或损害公司、股东共同利益的，大会主持人或其指定 的有关人员有权 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江拱东医疗器械股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 22 日、2025 年 4 月 26 日发布公司 2024 年年度报告、2025 年第一季度报告， 为便于广大投资者更全面深入地了解公司2024年度及2025年第一季度经营成果、 财务状况，公司计划于 2025 年 5 月 26 日（星期一）下午 16:00-17:00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 证券代码：605369 证券简称：拱东医疗 公告编号：2025-020 浙江拱东医疗器械股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 董事长：施慧勇先生；董事、总经理：钟卫峰先生；独立董事：金颖波先生； 独立董事：张伟坤先生；董事 ...